Kevin Tang named CEO of Kezar Life Sciences as multiple directors and officers resign
I'm LongbridgeAI, I can summarize articles.Kezar Life Sciences has appointed Kevin Tang as the new Chief Executive Officer and sole director following the resignation of multiple directors and officers due to a merger. The resignations were not due to disagreements, and the individuals involved entered into separation agreements. Tang, who previously served as the sole director of the merger subsidiary, will lead the surviving corporation.
Kezar Life Sciences said Kevin Tang became Chief Executive Officer and sole director of the surviving company at the Effective Time as multiple current directors and officers resigned in connection with the Merger.
| Individual | John Fowler | Franklin Berger | Graham Cooper | Elizabeth Garner, M.D. | Michael Kauffman, M.D., Ph.D. | Micki Klearman, M.D. | Courtney Wallace | Christopher J. Kirk, Ph.D. | Marc L. Belsky | Mark Schiller | Kevin Tang | Ryan Cole | Michael Hearne | Stephen Robertson |
| Role | Director | Director | Director | Director | Director | Director | Director | Officer (separation agreement) | Officer (separation agreement) | Officer (separation agreement) | Chief Executive Officer; Sole director (Merger Sub prior) | Chief Operating Officer (Merger Sub prior) | Chief Financial Officer (Merger Sub prior) | Chief Legal Officer, Corporate Secretary and Chief Compliance Officer (Merger Sub prior) |
| Type of Change | Resigned | Resigned | Resigned | Resigned | Resigned | Resigned | Resigned | Terminated (employment) at Effective Time | Terminated (employment) at Effective Time | Terminated (employment) at Effective Time | Appointed as sole director and officer of Surviving Corporation at Effective Time | Appointed as officer of Surviving Corporation at Effective Time | Appointed as officer of Surviving Corporation at Effective Time | Appointed as officer of Surviving Corporation at Effective Time |
| Effective Date | At the Effective Time | At the Effective Time | At the Effective Time | At the Effective Time | At the Effective Time | At the Effective Time | At the Effective Time | At the Effective Time | At the Effective Time | At the Effective Time | At the Effective Time | At the Effective Time | At the Effective Time | At the Effective Time |
| Reason | Resignation in connection with the Merger; not due to disagreements | Resignation in connection with the Merger; not due to disagreements | Resignation in connection with the Merger; not due to disagreements | Resignation in connection with the Merger; not due to disagreements | Resignation in connection with the Merger; not due to disagreements | Resignation in connection with the Merger; not due to disagreements | Resignation in connection with the Merger; not due to disagreements | Entered into separation agreement; no disagreements with the Company | Entered into separation agreement; no disagreements with the Company | Entered into separation agreement; no disagreements with the Company | Per Merger Agreement (Merger Sub became Surviving Corporation) | Per Merger Agreement (Merger Sub became Surviving Corporation) | Per Merger Agreement (Merger Sub became Surviving Corporation) | Per Merger Agreement (Merger Sub became Surviving Corporation) |
| Replacement Info | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Kevin Tang was sole director of Merger Sub prior to Effective Time and became sole director/officer of Surviving Corporation | Became officer of Surviving Corporation | Became officer of Surviving Corporation | Became officer of Surviving Corporation |
| Background Details | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Entered separation agreement (previously disclosed Apr 3, 2026) | Entered separation agreement (previously disclosed Apr 3, 2026) | Entered separation agreement (previously disclosed Apr 3, 2026) | Served as sole director and CEO of Merger Sub immediately prior to Effective Time | Served as COO of Merger Sub immediately prior to Effective Time | Served as CFO of Merger Sub immediately prior to Effective Time | Served as Chief Legal Officer, Corporate Secretary and Chief Compliance Officer of Merger Sub immediately prior to Effective Time |
| Board/Committee Role Changes | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Not disclosed |
Original SEC Filing: Kezar Life Sciences, Inc. [ KZR ] - 8-K - May. 11, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.